YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According…
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, announced that the U.S. Food and Drug Administration or FDA has granted Fast Track designation to Pelareorep in combination with a checkpoint inhibitor in…
(RTTNews) - Oncolytics Biotech Inc. (ONCY) has secured a new U.S. Patent that extends protection over the commercial manufacturing process of its investigational immunotherapy Pelareorep, marking another step in the company's long-term int…
Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Oncolytics Biotech, Inc. SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunoth…
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest batt…
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to the 4–6 months historical benchmarks. The com…
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Monday announced that it has scheduled a Type C meeting with the U.S. Food and Drug Administration FDA on April 16, 2026, to discuss a potential registr…
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing…
[Cancer cells vis] koto_feja/E+ via Getty Images * Oncolytics Biotech (ONCY [https://seekingalpha.com/symbol/ONCY]) traded higher on Tuesday after the Canadian biotech company announced that it has decided to end enrollment in its Phase 1/…
VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Equity InsiderMarket Intelligence Brief — WHAT’S HAPPENING: Gold above $5,000 per ounce[1]. The White House mobilized $12 billion for critical mineral stockpiling[2]. The FDA a…
[Colon cancer. Cancer attacking cell. Colon disease concept. 3d illustration] Mohammed Haneefa Nizamudeen * Oncolytics Biotech (ONCY [https://seekingalpha.com/symbol/ONCY]) is up ~15% in premarket trading Wednesday after announcing that th…
VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The era of abundance has reached its limit. The speculative fever of the last decade has been replaced by a scramble for the "Choke…
Oncolytics Biotech, Inc. Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed programs in gastrointestinal cancers SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE)…
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, Jan. 12, 2026 (G…
Oncolytics Biotech Inc. (NASDAQ:ONCY) is included in our list of the stocks under $1 that will explode.Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances Oncolytics Biotech Inc. (NASDAQ:ONCY) shared a leadership update…
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to…
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways th…
VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on momentum, entire subsectors have been left behind, cre…
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This c…
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This c…
[Human Pancreatic Cancer] wildpixel * Oncolytics Biotech (ONCY [https://seekingalpha.com/symbol/ONCY]) and the US FDA have agreed on a pivotal study design for pelareorep in combination as a first-line treatment of metastatic pancreatic du…
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment pa…
Oncolytics Biotech (NASDAQ:ONCY [https://seekingalpha.com/symbol/ONCY]) has established a new at-the-market equity financing agreement with BTIG, LLC. As disclosed in a Securities and Exchange Commission (SEC) filing [https://seekingalpha.…
Wall Street is looking for new ways to park cash in healthcare names, and large-cap biotechs have begun to gain steam. This asset class differs from traditional large-cap pharmaceutical companies — typically with a $200 billion market cap…
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected all eight director nominees at its Annua…
* Oncolytics Biotech press release [https://seekingalpha.com/pr/20194961-oncolytics-biotech-reports-second-quarter-financial-results-and-details-clinical-program] (NASDAQ:ONCY [https://seekingalpha.com/symbol/ONCY]): Q2 GAAP EPS of -$0.07.…
Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and exe…
Onc stock reached a significant milestone, hitting a 52-week high of 309.25 USD. The $36.11 billion market cap company’s achievement reflects a robust performance over the past year, during which BeOne Medicines AG DRC, the company behind…
SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a $34.64 billion market cap company, has regained compliance with Nasdaq’s minimum bid price requirement, according to a formal notice received Tuesday from the exchange’…
Investing.com - RBC Capital has raised its price target on BeOne Medicines (NASDAQ:ONC) to $349.00 from $311.00 while maintaining an Outperform rating on the stock. The company, currently trading at $278, has seen its shares surge 76% over…
SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage biotechnology company with a market capitalization of approximately $108 million, announced Wednesday that integrated biomarker analyses from multiple cl…
PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions o…
SAN DIEGO and CALGARY, Alberta, June 30, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as C…
PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization…
PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of diagnoses, with the aggressive nature of the…